Clinical trial · Interventional
A Study of PTS for Patients With Solid Tumors
A Phase I Open-Label, Dose-Escalation Study of Para-toluenesulfonamide Injection (PTS) Administered Intratumorally and Locally to Patients With Solid Tumors
NCT03448211CI-TRIAL-00032382withdrawnPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Development strategy reasons
Summary
Brief summary (as posted)
The primary objective of this study is to determine the MTD of PTS following local and intratumoral injections over a treatment course of two 5-day cycles to patients with palpable advanced solid malignancies who have failed standard treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Para-toluenesulfonamide Injection (PTS) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Para-toluenesulfonamide Injection (PTS)
- description
- Investigational product
- interventionNames
- Drug: Para-toluenesulfonamide Injection (PTS)
Primary outcomes (1)
- measure
- Maximum tolerable dose
- timeFrame
- 4 weeks post-treatment
- description
- Maximum tolerable dose
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects are diagnosed as unsuitable for surgical operations or refuse to do so. * Subject's performance status is classified as Grade 0 to Grade 3. Estimated survival time should be longer than 6 months of time. * Physical examinations show no serious functional disorders of the heart, liver, kidneys, or blood. * Subjects were treated with radio or chemotherapy previously. A minimum of 2 to 3 months recovery time is required before treating with this investigational drug. * Subject is diagnosed as intratracheal lesions with metastasized pulmonary cancer not suitable for surgery, or refuses to be operated. * Subject should show lobular atelectasis with either complete or incomplete obstruction of the bronchi. * Physical examinations should show no functional disorders of the heart, liver, kidneys, central nervous system, and blood. * Subject performance status to be classified from Grade 0 to Grade 3, who can tolerate the fiberoptic bronchoscopy treatments. * In-patient is preferred. When subject is in satisfactory conditions, the out Cpatient can also be enrolled in this trial. * Two to three months recovery time is required for the subject has just received radio or chemotherapy. * Emergency request, subjects with serious lobular atelectasis and almost complete obstruction of the bronchi. * With the aid of a tracheal intubation and the help of the respirator, PTS may be intraumorally injected into the obstructed lesion via fiberoptic bronchoscopy outside of the tube, alongside of the intubation. Exclusion Criteria: * Pregnant women and children will not be used as test subjects. * Subjects with serious functional disorders of the heart, liver, kidneys, or blood will be excluded. * Subjects who do not want to participate in the trial will not be used as test subjects. * Subject does not agree to participate. * Subject performance status is Grade 4, and the one who does not want to tolerate the discomfort of the PTS treatments via fiberoptic bronchscopy.
References
Publications (0)
Data not yet available
No reference posted for this study.